Building III
Bierutowska 57-59 Street
Wroclaw 51-317
Poland
48 71 880 8771
https://bioceltix.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 28
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Mr. Lukasz Bzdzion | President of the Management Board | 367.52k | N/A | N/A |
Mr. Pawel Wielgus | Member of the Management Board | 359.13k | N/A | N/A |
Andrij Wlach | Chief Financial Officer | N/A | N/A | N/A |
Mr. Grzegorz Ostropolski | Chief Operating Officer | N/A | N/A | N/A |
Dr. Jakub Grzesiak Ph.D. | Technology Director | N/A | N/A | N/A |
Bioceltix S.A. engages in the development of stem cell-based biopharmaceuticals for veterinary use. Its products include BCX-CM-J, a stem-cell based biological drug for the treatment of degenerative joint lesions in dogs; BCX-CM-AD, a biological drug candidate based on allogeneic stem cells for the treatment of atopic dermatitis in dogs; and BCX-EM, a biological drug candidate based on allogeneic mesenchymal stem cells for the treatment of arthritis in horses. The company was incorporated in 2018 and is based in Wroclaw, Poland.
Bioceltix S.A.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.